ERBB2 and neoplasm: Figs. 8A–8B show intensity map of the 16 pixels at the tumor region and contralateral site before injection of the Affibody probe. A comparison between the autofluorescence (before injection) and the fluorescence signal after injection of (A) HER2 specific Affibody-Dylight750 (B) HER2 non-specific Affibody-Dylight750 in mice with NCI-N87 tumor xenografts is presented in Figs. 8C–8D for the tumor and the contralateral sites, respectively.